LONDON, March 9, 2016 /PRNewswire/ -- Smith & Nephew
(NYSE: SNN; LSE: SN), the global medical technology business, today
announced the launch of the TRUCLEAR 5C Hysteroscope Set for the
combined diagnosis and removal of abnormalities within the uterine
cavity. The ability to identify and remove intrauterine pathologies
using a single scope is known as "see-and-treat" by surgeons and
reduces the need for patients to schedule multiple visits.
The 5C Hysteroscope builds on the success of the innovative
TRUCLEAR 5.0 System, which studies suggest may represent the best
choice for office hysteroscopy.i A recent scientific
review of published data related to 1,184 patients demonstrated
that the TRUCLEAR 5.0 System outperformed conventional resectoscopy
and conventional outpatient operative hysteroscopy on such issues
as safety, efficacy, surgical complications, estimated learning
curve and operating time. i
According to gynecologist feedback gathered after using the 5C
device, the new 5C Hysteroscope's slanted tip allowed for easier
insertion into the cervix, thus minimizing the need for dilation
and potentially improving the overall patient
experience.ii
"The TRUCLEAR 5C Hysteroscope Set allows me to perform both
diagnostic and operative hysteroscopy in a way that is more
efficient for both me and my patients," says Dr. Daniel B. Williams of Houston Fertility
Institute. "If polyps or fibroids are identified, I am then
able to use the TRUCLEAR System for pathology removal without
changing scopes."
"We are excited by the opportunity the TRUCLEAR 5C offers
surgeons to diagnose and treat uterine abnormalities in the most
efficient and patient-friendly way possible," said Mira Sahney, General Manager for ENT and
Gynecology at Smith & Nephew. "And as clinical evidence
continues to support the use of office-based hysteroscopic
procedures, we will continue to pioneer advancements that help save
healthcare resources and avoid unnecessary hospital
admissions."
About TRUCLEAR Procedure
During the procedure, a scope (known as a hysteroscope) is
inserted through the cervix allowing the gynecologist to see inside
the uterus. Through that same scope, the doctor then inserts small
instruments that mechanically cut and remove tissue, such as polyps
and fibroids, from the uterus. Unlike some other treatment
options, the mechanical design of the TRUCLEAR Procedure means
there is no risk of electrical injury to the lining of the
uterus.
For detailed product information, including indications for use,
contraindications, effects, precautions and warnings, please
consult the product's Instructions for Use (IFU) prior to use at
www.sntruclear.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2015 were more
than $4.6 billion. Smith & Nephew
is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
™ Trademark of Smith &
Nephew. Certain marks registered US Patent and Trademark
Office.
i Noventa, M. MD, Ancona, E., MD, Quaranta, M., MD,
Vitagliano, A., MD, Cosmi, E., MD, D'Antona, D., MD, and Gizzo, S.,
MD. (2015)
"The Icon of Hysteroscopic Future or Merely a Marketing Image? A
Systematic Review Regarding Safety, Efficacy, Advantages and
Contraindications". Reproductive Sciences, Published Online.
ii Data on file
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/new-see-and-treat-truclear-hysteroscope-improves-options-for-office-hysteroscopy-300233114.html
SOURCE Smith & Nephew